Special Issue "Neurological Complications Following COVID-19 Infection and COVID-19 Vaccination"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 10420
Interests: global health; public health; health disparities; global neurosurgery; global neurology; neuroscience
Special Issues, Collections and Topics in MDPI journals
Since 2019, the COVID-19 pandemic has accounted for more than 400 thousand deaths globally, with reports suggesting that COVID-19 infection is associated with increased risk of thrombosis and stroke. In addition, data from survivors who are experiencing long COVID-19 still indicate that some neurological complications are associated with the disease. Although these reports are rare, they are important in enabling health professionals to fully understand the disease and improve the existing management of COVID-19 patients.
On the other hand, several COVID-19 vaccines have been developed, evaluated, and approved for roll-out in the population, with clinical trials and real-life data confirming their general safety and efficacy. The vaccines are generally effective and safe to administer to the population, except for some high-risk individuals who experience rare side effects, such as vaccine-induced thrombocytopenia, upon taking adenovirus-associated vaccines. The COVID-19 vaccine uses different technologies and can be adenovirus-associated, mRNA-based, or live-attenuated. Although these approved vaccines are effective in reducing the severity of COVID-19, they have variable safety profiles; therefore, the accurate selection of individuals who can be administered these vaccines is required for maximum safety. A few case reports have shown the occurrence of very uncommon neurological complications following vaccination, such as facial nerve palsy and Guillain-Barre syndrome.
The neurological complications associated with COVID-19 itself and COVID-19 vaccines have still not been extensively studied, and as such, are not fully understood. Therefore, the focus of this Special Issue is on neurological complications following COVID-19 and COVID-19 vaccines.
Dr. Ahmed Negida
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- global health
- neurological complications